serous cystadenocarcinoma

Summary

Summary: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)

Top Publications

  1. ncbi Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
    David W Kindelberger
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Surg Pathol 31:161-9. 2007
  2. ncbi Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
  3. pmc New insights into the pathogenesis of serous ovarian cancer and its clinical impact
    Keren Levanon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5284-93. 2008
  4. ncbi Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma
    Yan Huang
    Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 419 Fang Xie Road, Shanghai 200011, China
    Cell Res 18:780-91. 2008
  5. ncbi Histologic types of epithelial ovarian cancer: have they different risk factors?
    Allison W Kurian
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820, USA
    Gynecol Oncol 96:520-30. 2005
  6. ncbi Serous carcinogenesis in the fallopian tube: a descriptive classification
    Elke Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:1-9. 2008
  7. ncbi The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis
    Reiko Dehari
    Department of Pathology, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Surg Pathol 31:1007-12. 2007
  8. ncbi A candidate precursor to serous carcinoma that originates in the distal fallopian tube
    Y Lee
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Pathol 211:26-35. 2007
  9. pmc Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta
    K Rask
    Department of Physiology, Goteborg University, Goteborg, Sweden
    Br J Cancer 89:1298-304. 2003
  10. pmc Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
    Kuan Ting Kuo
    Departments of Pathology, Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Am J Pathol 174:1597-601. 2009

Detail Information

Publications214 found, 100 shown here

  1. ncbi Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
    David W Kindelberger
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Surg Pathol 31:161-9. 2007
    ....
  2. ncbi Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
    ..Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs...
  3. pmc New insights into the pathogenesis of serous ovarian cancer and its clinical impact
    Keren Levanon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5284-93. 2008
    ..With the rise of the fallopian tube secretory epithelial cell as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model systems to characterize the biology and physiology of this cell is recognized...
  4. ncbi Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma
    Yan Huang
    Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 419 Fang Xie Road, Shanghai 200011, China
    Cell Res 18:780-91. 2008
    ..We further showed that ovarian serous cystadenocarcinoma samples had much higher incidence of positive AKT and phosphorylated AKT (pAKT) protein staining than ..
  5. ncbi Histologic types of epithelial ovarian cancer: have they different risk factors?
    Allison W Kurian
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820, USA
    Gynecol Oncol 96:520-30. 2005
    ..The goals of the current study were to characterize further the relation of histologic-specific ovarian cancer risks to reproductive and lifestyle attributes...
  6. ncbi Serous carcinogenesis in the fallopian tube: a descriptive classification
    Elke Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 27:1-9. 2008
    ..Combined with recent reports associating STICs with pelvic serous cancer, this continuum of epithelial change validates the SCAT sequence and the fimbrial secretory cell as the site of origin for many serous carcinomas...
  7. ncbi The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis
    Reiko Dehari
    Department of Pathology, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Surg Pathol 31:1007-12. 2007
    ..The above results suggest that the majority of high-grade and low-grade carcinomas develop independently but in rare cases, a high-grade serous carcinoma may arise from an atypical proliferative serous (borderline) tumor...
  8. ncbi A candidate precursor to serous carcinoma that originates in the distal fallopian tube
    Y Lee
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Pathol 211:26-35. 2007
    ....
  9. pmc Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta
    K Rask
    Department of Physiology, Goteborg University, Goteborg, Sweden
    Br J Cancer 89:1298-304. 2003
    ..However, it remains to be demonstrated whether it is an increased participation of beta-catenin in transcriptional regulation, or in the stabilisation of cellular integrity, or both, that is the crucial event in ovarian tumorigenesis...
  10. pmc Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma
    Kuan Ting Kuo
    Departments of Pathology, Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Am J Pathol 174:1597-601. 2009
    ..We therefore suggest that the use of PIK3CA-targeting drugs may offer a more effective therapeutic approach compared with current chemotherapeutic agents for patients with advanced-stage and recurrent CCC...
  11. ncbi Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment
    Charles Galanis
    Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Gastrointest Surg 11:820-6. 2007
    ..Serous cystic neoplasms of the pancreas are regarded as a benign entity with rare malignant potential. Surgical resection is generally considered curative...
  12. ncbi Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma
    Shannon Salvador
    Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
    Gynecol Oncol 110:408-17. 2008
    ..Recent studies suggest these cancers may arise in the fallopian tube. This study explores the relationship between ovarian cancers and fallopian tube mucosal involvement...
  13. ncbi Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation
    Gad Singer
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Am J Surg Pathol 29:218-24. 2005
    ....
  14. ncbi Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer
    Kristin K Zorn
    National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 11:6422-30. 2005
    ..This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors...
  15. ncbi Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Cancer 112:14-25. 2004
    ..NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type-specific therapies against this disease...
  16. ncbi Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
    Cancer 100:1045-52. 2004
    ..Comparison of the survival for women with LMP tumors staged as distant with women who have carcinoma may have important implications for diagnostic terminology and clinical management...
  17. ncbi Distinct subtypes of serous ovarian carcinoma identified by p53 determination
    Heini Lassus
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Haartmaninkatu 2, 00290, Helsinki, Finland
    Gynecol Oncol 91:504-12. 2003
    ..We investigated the value of p53 expression as a disease determinant in serous carcinoma, which is the most common type of ovarian carcinoma and has shown the highest frequency of p53 alterations...
  18. pmc Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas
    J Tapper
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland
    Br J Cancer 75:1782-7. 1997
    ..The diverging pattern of genetic changes seen in epithelial ovarian carcinomas with different histological phenotypes suggests that various pathways may lead to tumorigenesis and/or progression in these subgroups...
  19. ncbi Grading ovarian serous carcinoma using a two-tier system
    Anais Malpica
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 28:496-504. 2004
    ..However, additional studies are required to validate these statements...
  20. ncbi Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
    Rebecca T Marquez
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6116-26. 2005
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  21. ncbi Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer
    Anish Bali
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales
    Clin Cancer Res 10:5168-77. 2004
    ..However, the prognostic significance of aberrant cell cycle gene expression in EOC remains unclear...
  22. ncbi Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations
    Gudrun Pohl
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 65:1994-2000. 2005
    ....
  23. ncbi Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas
    Karolina Partheen
    Department of Oncology, University of Gothenburg, Gothenburg, Sweden
    Int J Cancer 123:2130-7. 2008
    ..According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas...
  24. pmc Pancreatic serous cystadenocarcinoma: a case report and review of the literature
    Jonathan C King
    Department of Surgery, David Geffen School of Medicine at UCLA, Box 956904, 72 170 CHS, Los Angeles, CA 90095 6904, USA
    J Gastrointest Surg 13:1864-8. 2009
    Serous cystic neoplasms of the pancreas are benign lesions with little chance for malignant degeneration. We report a case of malignant serous cystadenocarcinoma of the pancreas and review the literature.
  25. ncbi Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features
    Sharon X Liang
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8070, USA
    Int J Surg Pathol 12:319-31. 2004
    ..The clinical significance of EmGD needs further studies...
  26. ncbi Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?
    Guo Xia Tong
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Mod Pathol 20:856-63. 2007
    ....
  27. ncbi Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary
    Tomas Bonome
    Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:10602-12. 2005
    ..Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype...
  28. ncbi Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
    ..We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy...
  29. ncbi Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues
    A W Brandenberger
    Reproductive Endocrinology Center, University of California, San Francisco, 94143 0556, USA
    J Clin Endocrinol Metab 83:1025-8. 1998
    ..HEY did not contain detectable amounts of either ER after 40 cycles of RT-PCR. We found no evidence of differential splicing or major deletions in almost the entire coding region of ER-beta in either normal ovaries or tumor samples...
  30. ncbi Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance
    R Salani
    The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Int J Gynecol Cancer 18:487-91. 2008
    ..3%, which is much higher than previously reported. Furthermore, we found that TP53 is not directly involved in the development of drug resistance in high-grade ovarian serous carcinomas...
  31. pmc Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, UAMS Medical Center, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Br J Cancer 90:1814-24. 2004
    ..A therapeutic strategy targeting HER-2/neu may be beneficial in patients harbouring chemotherapy-resistant USPC...
  32. ncbi Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4
    H Lassus
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Lab Invest 81:517-26. 2001
    ..Our results suggest distinct pathogenetic pathways in serous and mucinous ovarian carcinomas and the presence of more than one tumor suppressor gene at 8p involved in the tumorigenesis of serous carcinoma...
  33. ncbi Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin
    Harry Hwang
    PhenoPath Laboratories, 551 N 34th Street, Seattle, WA 98103, USA
    Appl Immunohistochem Mol Morphol 12:122-6. 2004
    ..These results also contradict recent reports demonstrating WT-1 expression in both breast and lung carcinomas...
  34. ncbi Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma
    Lin Jia
    Department of Pathology, Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ 85724, USA
    Clin Cancer Res 14:2263-9. 2008
    ..The purpose of this study is to determine if EmGD is genetically linked to ESC and if it can be used for early detection...
  35. ncbi Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Pathol 26:404-9. 2007
    ..These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC...
  36. ncbi Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors
    B H Ortiz
    Laboratory of Gynecological Oncology, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 61:7264-7. 2001
    ..These findings are consistent with the hypothesis that advanced-stage serous BOTs represent a distinct pathological entity compared with grade 1 serous epithelial ovarian carcinoma...
  37. ncbi Histologic and immunohistochemical decision-making in endometrial adenocarcinoma
    Lesley Lomo
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 21:937-42. 2008
    ..Because p53 is an important marker for endometrial adenocarcinoma outcome, and cannot be predicted in advance in indeterminate cases, p53 immunostaining should be employed in cases with observer disagreement in a binary system...
  38. ncbi Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking
    T Le
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario, Canada
    Int J Gynecol Cancer 16:986-90. 2006
    ..97, 95% CI 1.01-3.87, P= 0.048). The estimated median survival was 50.66 months (95% CI 46.12-55.20). The lack of or minimal tumor necrosis after neoadjuvant chemotherapy is an independent risk factor for recurrent disease...
  39. ncbi Risk factors for different histological types of ovarian cancer
    F Parazzini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Int J Gynecol Cancer 14:431-6. 2004
    ..7) and endometrioid (OR = 0.8) ovarian cancers but not for mucinous (OR = 1.4) and other histologies (OR = 1.6). Finally, our results on dietary fat intake did not show substantial differences in all histological types of ovarian cancer...
  40. ncbi Risk of malignancy in serous cystic neoplasms of the pancreas
    Oliver Strobel
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    Digestion 68:24-33. 2003
    ..There are, however, several reports of malignancy in serous cystic neoplasms of the pancreas...
  41. ncbi Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Clin Cancer Res 11:3320-5. 2005
    ..The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer...
  42. ncbi Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis
    Susan J Jordan
    Cancer and Population Studies Group, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Int J Cancer 122:1598-603. 2008
    ..These results also call into question the role of the physical effects of ovulation in the development of serous ovarian cancer...
  43. ncbi Precursors to pelvic serous carcinoma and their clinical implications
    Ann K Folkins
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Gynecol Oncol 113:391-6. 2009
    ..The data supporting a candidate precursor, the implications of these findings for early detection and prevention of pelvic serous carcinoma and the caveats, are discussed...
  44. ncbi ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma
    Heini Lassus
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
    Gynecol Oncol 92:31-9. 2004
    ..In addition, concordance of the findings of ERBB2 immunohistochemistry and ERBB2 amplification was assessed...
  45. ncbi Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential
    Marta A Crispens
    Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9640, USA
    Obstet Gynecol 99:3-10. 2002
    ..To evaluate the response to therapy and survival of patients with progressive or recurrent serous ovarian tumors of low malignant potential...
  46. ncbi Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas
    Bernard Tetu
    Department of Pathology, Centre Hospitalier Universitaire de Quebec, L Hôtel Dieu de Québec, Faculty of Medicine, Laval University Quebec, Quebec City, Quebec, Canada
    Mod Pathol 21:1002-10. 2008
    ..61; CI: 0.94-2.79; P=0.08). Our study shows that gene expression analysis coupled with immunohistochemistry allowed the identification of HSP10 as an independent factor of progression-free survival...
  47. ncbi Role of cytoreduction in stage III and IV uterine papillary serous carcinoma
    M Bijoy Thomas
    Division of Gynecologic Surgery, Mayo Clinic, 200 1st St NW, Rochester, MN 55905, USA
    Gynecol Oncol 107:190-3. 2007
    ..Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC...
  48. ncbi Epidemiology of low-grade serous ovarian cancer
    Steven C Plaxe
    Division of Gynecologic Oncology, Department of Reproductive Medicine, Rebecca and John Moores University of California, San Diego, Cancer Center, San Diego, CA, USA
    Am J Obstet Gynecol 198:459.e1-8; discussion 459.e8-9. 2008
    ..The objective of the study was to determine whether the epidemiology of low-grade ovarian serous cancers is distinct from that of high-grade ovarian serous cancers...
  49. ncbi Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling
    C Blake Gilks
    Genetic Pathology Evaluation Centre of the Department of Pathology and Prostate Research Centre, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Canada
    Gynecol Oncol 96:684-94. 2005
    ..To further examine the molecular differences between these two diseases, we studied the gene expression pattern of ovarian S-LMP and S-Ca using high-density spotted cDNA and tissue microarrays...
  50. ncbi Serous cystadenocarcinoma of the pancreas: management of a rare entity
    Veronica Friebe
    Department of General and Visceral Surgery, University of Freiburg, Freiburg, Germany
    Pancreas 31:182-7. 2005
    ..case of an 80-year-old woman with a primary tumor of the pancreas that was histologically classified as serous cystadenocarcinoma. Because preoperatively available criteria that determine malignancy in serous lesions are lacking, ..
  51. ncbi Serous cystadenocarcinoma of the pancreas
    Masayuki Shintaku
    Department of Pathology, Osaka Red Cross Hospital, Tennoji, Osaka, Japan
    Pathol Int 55:436-9. 2005
    A case of serous cystadenocarcinoma of the pancreas in an 85-year-old woman is reported. The tumor extensively involved the body and tail of the pancreas and contiguously invaded the spleen...
  52. ncbi Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary
    Fumitoshi Terauchi
    Second Department of Obstetrics and Gynecology, Toho University School of Medicine, 2 17 6 Ohashi, Meguro ku, Tokyo 153 8515, Japan
    Oncol Rep 14:363-8. 2005
    ....
  53. ncbi Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways
    Howard Donninger
    Department of Cell and Cancer Biology, National Cancer Institute, Rockville, MD 20850, USA
    Oncogene 23:8065-77. 2004
    ....
  54. ncbi Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors
    Karolina Partheen
    Department of Oncology, Goteborg University, SE 413 45 Goteborg, Sweden
    Eur J Cancer 42:2846-54. 2006
    ..Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients...
  55. ncbi Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage
    Karolina Partheen
    Department of Oncology, Goteborg University, Goteborg, Sweden
    Genes Chromosomes Cancer 40:342-8. 2004
    ..On the basis of our results, we suggest that there are biological differences among the groups mentioned above and that absence of chromosomal aberrations in specific regions predicts a good clinical outcome for individual patients...
  56. ncbi Critical molecular abnormalities in high-grade serous carcinoma of the ovary
    Martin Köbel
    Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver BC, Canada
    Expert Rev Mol Med 10:e22. 2008
    ..These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice...
  57. ncbi High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy
    Jane E Hirst
    Department of Obstetrics and Gynecology, Royal North Shore Hospital, Sydney, Australia
    Int J Gynecol Cancer 19:826-9. 2009
    ..To determine the rate of occult malignancy in patients undergoing prophylactic bilateral salpingo-oophorectomy in Northern Sydney...
  58. pmc Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary
    Jong Hoon Lee
    Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
    J Korean Med Sci 17:415-8. 2002
    ..We report a case in which the resection of metastatic liver neoplasm from ovarian serous cystadenocarcinoma was done 7 yr after initial treatment...
  59. pmc Gene expression profiling of human ovarian tumours
    S Biade
    Department of Pharmacology, University of Pennsylvania Cancer Center, BRB II III Room 1020, 421 Curie Building, Philadelphia, PA, USA
    Br J Cancer 95:1092-100. 2006
    ..The data that we have generated will contribute to a growing body of expression data that more accurately define the biologic and clinical characteristics of ovarian cancers...
  60. ncbi Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
    N Engl J Med 346:1616-22. 2002
    ..We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations...
  61. ncbi Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors
    K Shigemasa
    Department of Obstetrics and Gynecology, Hiroshima University School of Medicine, Hiroshima 734 8551, Japan
    Int J Gynecol Cancer 11:454-61. 2001
    ....
  62. ncbi Geographical variations in TP53 mutational spectrum in ovarian carcinomas
    A Dansonka-Mieszkowska
    Department of Molecular Pathology, The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Ann Hum Genet 70:594-604. 2006
    ..002), while tumours from the UK shared the 273(CYS) codon (80%, p < 0.001). Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights...
  63. ncbi Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers
    Amir A Jazaeri
    Division of Clinical Sciences of the National Cancer Institute, Gaithersburg, MD, USA
    J Natl Cancer Inst 94:990-1000. 2002
    ....
  64. ncbi Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary
    Hiroaki Itamochi
    Department of Obstetrics and Gynecology, Tottori University, Yonago, Japan
    Oncology 62:349-53. 2002
    ..8 h). A significant reverse correlation between the S-phase fraction and the response to CDDP was observed (r = 0.647, p < 0.05). The present study suggests that the resistance of CCC to CDDP may be caused by low cell proliferation...
  65. ncbi Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
    Eleonora Karbova
    Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
    Int J Surg Pathol 10:175-80. 2002
    ..The mechanism behind the down-regulated expression of APC in serous ovarian carcinoma and its significance has yet to be elucidated...
  66. ncbi The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent
    Elvio G Silva
    Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 30:1367-71. 2006
    ..We propose that patients be followed for a minimum of 10 years to evaluate for recurrences and for 20 years to evaluate for survival...
  67. ncbi Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma
    I Skirnisdottir
    Department of Gynecology and Obstetrics, University Hospital, Akademiska sjukhuset, SE 751 85 Uppsala, Sweden
    Int J Oncol 19:1295-302. 2001
    ..Overexpression of p53 also increases the risk of tumor recurrence...
  68. ncbi Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma
    F Kayikcioglu
    SSK Ankara Maternity Hospital, Department of Gynecologic Oncology, Etlik, Ankara, Turkey
    Int J Gynecol Cancer 11:466-70. 2001
    ..Primary chemotherapy followed by interval debulking surgery in a selected group of patients does not appear to worsen prognosis, but it permits less aggressive surgery and improves patients' quality of life...
  69. ncbi Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma
    K Pillay
    Department of Pathology, Nelson R. Mandela School of Medicine, Faculty of Health Sciences, University of Natal, Congella, Durban, South Africa
    Int J Surg Pathol 9:317-21. 2001
    ..The tumor behaved aggressively because of the angiosarcomatous component, and since the patient was assessed as having stage IV disease, no further treatment was offered...
  70. ncbi The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis
    C Simon Herrington
    Bute Medical School, University of St Andrews and Department of Pathology, Ninewells Hospital, Dundee, UK
    J Pathol 220:5-6. 2010
    ..In addition to its biological significance, this, if proven, has clear clinical implications...
  71. ncbi Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)
    Gad Singer
    Department of Pathology, The Johns Hopkins University School of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Int J Gynecol Pathol 22:37-41. 2003
    ..The results indicate that CSCs with micropapillary features are not derived from invasive MPSCs. The molecular findings also support the view that ovarian serous carcinomas should be graded as low- and high-grade tumors...
  72. ncbi Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up
    Teri A Longacre
    Department of Pathology, Stanford University, 300 Pasateur Drive, Stanford, CA 94305, USA
    Am J Surg Pathol 29:707-23. 2005
    ..The small, but significant risk of progression over time to low-grade serous carcinoma emphasizes the need for prolonged follow-up in patients with S-LMP...
  73. ncbi Familial invasive and borderline ovarian tumors by proband status, age and histology
    Kari Hemminki
    Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
    Int J Cancer 105:701-5. 2003
    ..Histopathology and age of onset appear to be important attributes of familial ovarian cancer, suggesting that further gene identification efforts should target a specific histopathology in early-onset patients...
  74. ncbi Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining
    Krittaya Kritpracha
    Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
    J Obstet Gynaecol Res 31:268-76. 2005
    ....
  75. ncbi MicroRNA expression profiles in serous ovarian carcinoma
    Eun Ji Nam
    Women s Cancer Clinic, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
    Clin Cancer Res 14:2690-5. 2008
    ..We assessed the expression of microRNA and the association between microRNA expression and the prognosis of serous ovarian carcinoma...
  76. ncbi Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma
    Hiroaki Kajiyama
    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai cho 65, Showa Ku, Nagoya 466 8550, Japan
    Int J Cancer 122:91-9. 2008
    ..The present results suggest that there may be a link between the SDF-1alpha/CXCR4 axis and enhanced intraperitoneal dissemination of EOC and that CXCR4 may be a novel target for the treatment of EOC...
  77. ncbi Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer
    Ryoko Kikuchi
    Department of Molecular Cytogenetics, Medical Research Institute and School of Biomedical Science, Tokyo Medical and Dental University, Japan
    Cancer Res 67:7095-105. 2007
    ....
  78. ncbi Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study
    John K Chan
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143 1702, USA
    Cancer 112:2202-10. 2008
    ..The purpose was to identify the factors predictive of recurrence and survival in patients with high-risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy...
  79. ncbi High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels
    J M Lancaster
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, 33612, USA
    Int J Gynecol Cancer 16:1529-35. 2006
    ..Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer...
  80. ncbi Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independe
    Ryosuke Osada
    Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto 390 8621, Japan
    Hum Pathol 38:1310-20. 2007
    ..These results show that the HIF-alpha subunit represents an important biomarker in the evaluation of the prognosis of patients with ovarian carcinoma...
  81. ncbi Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways
    Rong Wu
    Department of Pathology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 11:321-33. 2007
    ..The biological behavior and gene expression patterns of the murine cancers resemble those of human OEAs with defects in the Wnt/beta-catenin and PI3K/Pten pathways...
  82. ncbi Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
    Ingiridur Skirnisdottir
    Department of Gynecology and Obstetrics, University Hospital, Akademiska sjukhuset, Uppsala, SE 751 85, Sweden
    Oncol Rep 14:521-9. 2005
    ..However, further studies are needed to find the subgroup of patients who specifically might benefit from radiotherapy in this setting...
  83. ncbi Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients
    A Molckovsky
    Department of Oncology and Department of Obstetrics and Gynecology, Queen s University, Kingston, Ontario, Canada
    Int J Gynecol Cancer 18:8-13. 2008
    ..These results suggest that decreasing the frequency of chemotherapy cycles does not decrease survival. Prospective trials would be required to compare quality of life and cost-effectiveness...
  84. pmc A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
    R Fruscio
    Clinica Ostetrica e Ginecologica, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy
    Br J Cancer 98:720-7. 2008
    ..This unexpected finding might be a consequence of the close surgical surveillance and aggressive chemotherapeutic approach...
  85. ncbi Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma
    Ingiridur Skirnisdottir
    Department of Women s and Children s Health, Obstetrics and Gynecology, University Hospital, Akademiska sjukhuset, SE 751 85 Uppsala, Sweden
    Oncol Rep 18:1249-56. 2007
    ..The spectrum of side effects was also in favor of the monotherapy regimen. Further, larger randomized studies are needed to give a final and fully conclusive answer to this question...
  86. ncbi Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types
    Huamin Wang
    Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 19:1149-56. 2006
    ..We concluded that IGFBP2 and IGFBP5 might play a role in the development of high-grade ovarian serous carcinoma, but not in mucinous or clear cell ovarian carcinomas...
  87. ncbi [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]
    M Buttarelli
    Service de Chirurgie Oncologique 2, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, BP 156, 13273 Marseille Cedex 09, France
    Ann Chir 131:431-6. 2006
    ..The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary...
  88. ncbi TTF-1 expression in primary ovarian epithelial neoplasia
    A D Graham
    Histopathology 48:764-5. 2006
  89. pmc Population attributable fractions for ovarian cancer in Swedish women by morphological type
    C Granström
    Department of Neurobiology, Caring Sciences and Society, Center for Family and Community Medicine, Karolinska Institute, Alfred Nobels alle 12, Huddinge 141 83, Sweden
    Br J Cancer 98:199-205. 2008
    ..The risks for women with a family history were among the highest, but these women accounted for the smallest proportion of the cases, giving the lowest PAFs...
  90. ncbi The prognostic significance of elongation factor eEF1A2 in ovarian cancer
    Dixie E Pinke
    Department of Biochemistry, Microbiology, Immunology, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada K1H 8M5
    Gynecol Oncol 108:561-8. 2008
    ..To determine whether eukaryotic elongation factor 1 alpha 2 (eEF1A2), a transforming gene previously shown to be highly expressed in primary human ovarian tumours, is a prognostic marker...
  91. ncbi Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 12:1487-93. 2006
    ..001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer...
  92. ncbi Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin
    Yuko Ueno
    Department of Obstetrics and Gynecology, Osaka University Faculty of Medicine, 2 2 Yamadaoka, Suita 565 0871, Osaka, Japan
    Cancer Lett 241:289-300. 2006
    ..Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors...
  93. ncbi Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine
    Bin Ye
    Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women s Hospital, Harvard Medical School, Dana Farber Cancer Center, 221 Longwood Avenue, LMRC 601B, Boston, MA 02115, USA
    Clin Cancer Res 12:432-41. 2006
    ..The objective was to identify and characterize low molecular weight proteins/peptides in urine and their posttranslational modifications that might be used as a screening tool for ovarian cancer...
  94. ncbi Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking
    Tien Le
    Division of Gynecologic Oncology, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Ann Surg Oncol 13:1711-6. 2006
    ..To examine the prognostic significance of postoperative morbidities in patients with ovarian cancer treated with neoadjuvant chemotherapy and interval surgical debulking...
  95. pmc Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers
    S M Alam
    Department of Obstetrics and Gynecology, Gifu University School of Medicine, Yanagido 1 1, Gifu City 501 1194, Japan
    Br J Cancer 98:845-51. 2008
    ..Thus, EphB4/ephrinB2 can be recognised as a novel prognostic indicator in the primary tumours of ovarian cancers...
  96. ncbi Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study
    William E Winter
    Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    J Clin Oncol 26:83-9. 2008
    ..To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC)...
  97. ncbi The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
    Hakan Karagol
    Department of Medical Oncology, Faculty of Medicine, Trakya University, Turkey
    Med Oncol 24:39-43. 2007
    ..In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma...
  98. ncbi HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features
    Takayo Ota
    Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada
    Reprod Sci 14:605-14. 2007
    ..HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization...
  99. ncbi B7-H4 overexpression in ovarian tumors
    Barbara Tringler
    Department of Pathology, University of Colorado Health Sciences Center, B 216, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Gynecol Oncol 100:44-52. 2006
    ....
  100. ncbi Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
    Natacha Roger
    Service de Chirurgie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Ann Surg Oncol 15:333-8. 2008
    ....
  101. ncbi Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients
    Tamar Safra
    Department of Medical Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Acta Oncol 45:463-8. 2006
    ..7%) and nausea and vomiting in two (4.7%). Single agent gemcitabine is an attractive option for heavily pretreated EOC patients. The significant difference between platinum-sensitive and resistant patients' warrants further investigation...

Research Grants18

  1. Use of Antidepressants and Risk of Breast Cancer
    MARY ROSSING; Fiscal Year: 2003
    ..g., SSRIs or tricyclics), and individual drugs such as fluoxetine and paroxetine. Use of the pharmacy database will provide unbiased and complete exposure data relative to previous studies based on self-reported drug use. ..
  2. A Data Center for the Discovery of the Genetic Basis of Human Disease
    Larry J Shapiro; Fiscal Year: 2010
    ..and normal tissues derived from patients with acute myeloid leukemia, lung adenocarcinoma, glioblastoma, serous cystadenocarcinoma, and squamous carcinoma, as well as genomic analysis of complex genetic traits and the human microbiome...
  3. Dendritic Cell Immunotherapy for Cervical Cancer
    Alessandro Santin; Fiscal Year: 2004
    ..This study will determine whether E7 antigen-loaded autologous DC vaccination offers the potential of therapeutic benefit for patients with HPV16 or HPV18-associated cervical cancer. ..
  4. Prognostic Markers for Juvenile Pilocytic Astrocytomas
    Kwong Kwok Wong; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  5. Tumor metastasis: Biobehavioral mechanisms
    Anil K Sood; Fiscal Year: 2009
    ....
  6. Society of Gynecologic Investigation Annual Meeting
    Andrew Berchuck; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  7. Urine Protein Biomarker Exploration in Ovarian Cancer
    Bin Ye; Fiscal Year: 2006
    ..This project, if successful, could fundamentally shift the approach to the early detection of ovarian cancer and significantly improve the survival rate of cases detected. [unreadable] [unreadable]..
  8. Ovarian Cancer Detection Using H-NMR_Based Metabonomics
    Kunle Odunsi; Fiscal Year: 2006
    ..The proposed studies may lead to the identification of novel biomarkers for early detection of EOC, that will be evaluated further in prospective studies for early detection of EOC in general and high-risk populations. ..
  9. Pharmacogenetic Epidemiology of Birth Defects and Cancer
    Timothy Rebbeck; Fiscal Year: 2004
    ....
  10. EPIDEMIOLOGY OF SMOKING CESSATION--GENETIC INFLUENCES
    MARY ROSSING; Fiscal Year: 2002
    ..In the future, such knowledge may allow the identification of subgroups of individuals who are most likely to benefit from particular pharmacologic interventions. ..
  11. PROPHYLCTIC MASTECTOMY IN HEREDITARY BREAST CANCER
    Lynn Hartmann; Fiscal Year: 2002
    ..We will also define short- and long-term complications following PM. ..
  12. Regulation of BRCA1 Function by Protein Phosphatase 1
    Lih Ching Hsu; Fiscal Year: 2009
    ..Lastly, we will also identify regulators of PP1 alpha activity toward BRCA1. ..
  13. DIET AND DURATION OF CERVICAL HPV INFECTION
    MARC GOODMAN; Fiscal Year: 2009
    ....
  14. Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA
    Howard Hochster; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  15. Human Subjects Protection: Fox Chase to the Community
    Robert Young; Fiscal Year: 2003
    ..Provide these programs to Network IRBs. Appraise performance of IRB website. 6) Enhance efficiency of Fox Chase IRB office and staff to handle expanded responsibilities. ..
  16. Steroid Hormone Genes and Ovarian Cancer Risk
    Mary Anne Rossing; Fiscal Year: 2010
    ..The proposed study, by expanding our knowledge of the role of progestogens, estrogens, and androgens in the development of ovarian cancer, will inform efforts to develop effective strategies to prevent this disease. ..
  17. Tumor-reactive IgG in the diagnosis of ovarian cancer
    Douglas Taylor; Fiscal Year: 2005
    ..Ultimately, antigenic proteins, linked with histologic type and stage of disease, will be combined into the development of protein arrays to screen for circulating reactive IgG as an early diagnostic test. ..
  18. Epidemiology of Ovarian Cancer:New Hypotheses
    MARY ROSSING; Fiscal Year: 2006
    ..abstract_text> ..